Monday, November 28, 2022

Control-IQ Technology Continues to Demonstrate Positive and Sustained Real-World Benefits Across Diverse Cohorts of People with Diabetes

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and sustained benefits in a diverse cohort of people using the t:slim X2™ insulin pump with Control-IQ® technology. The data was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans.

“Our Control-IQ technology continues to be a great equalizer for people with insulin-intensive diabetes, as we consistently see positive clinical and quality-of-life improvement with its use, regardless of age, ethnicity, or prior therapy,” said Jordan Pinsker, MD, Vice President and Medical Director for Tandem Diabetes Care. “This evidence increases our motivation to bring new advances in technology to benefit people living with diabetes worldwide.”

Data presented at the conference comes from the Control-IQ Observational (CLIO) study, an ongoing real-world, longitudinal study of people using the t:slim X2 insulin pump with Control-IQ technology.

Summaries of ADA Scientific Sessions Presentations

Psychosocial Benefits of Using Control-IQ Technology: Long-term Outcomes from a Multi-Ethnic Adult Cohort with Type 1 Diabetes1

Named as an ADA Presidents’ Select Abstract Presentation, this analysis features patient-reported outcomes from an ethnically diverse cohort of 1,306 adults. Results demonstrated significant improvements in diabetes-specific quality of life, satisfaction with insulin delivery device, and reduction in diabetes-related burden over 12 months with Control-IQ technology. Psychosocial benefits of Control-IQ technology were experienced by all ethnic cohorts. Significantly improved quality of sleep was also noted for all participants using the system.

Evaluation of Long-Term Glycemic Outcomes by Ethnicity in Adults with Type 1 Diabetes Using Control-IQ Technology2

This study assessed relationships between ethnicity, baseline HbA1c, Glucose Management Indicator (GMI), and sensor Time in Range (TIR) (70-180mg/dL) for 1,045 adult CLIO participants (Asian, Black/African American, White, and Hispanic/Latino/Spanish). GMI at study end reflected glycemic improvements for all participants, with Black/African American participants showing a clinically relevant 0.7% overall reduction.

Long-term Glycemic Control in Adult Participants Using Control-IQ Technology: Real-World Evidence3

This study assessed baseline HbA1c and glucose management indicator derived from sensor data from 1,107 adults using Control-IQ technology for 12 consecutive months. Data demonstrated significant glycemic improvements, regardless of prior therapy modality.

Multiple daily injection users with relatively high HbA1c values initiating Control-IQ technology showed dramatic and sustained glycemic improvements. Previous pump users also demonstrated immediate and sustained improvements, continuing to build on evidence that all users can benefit from Control-IQ technology regardless of prior therapy.

“Demonstrating that our technology benefits ethnically diverse groups, irrespective of previous therapy modality, is critical to fulfilling our mission to improve the lives of people living with diabetes worldwide,” said Steph Habif, EdD, MS, Vice President, Behavioral Sciences at Tandem Diabetes Care. “As a global leader in insulin therapy management, we strive to provide diabetes care solutions that work equally well across all people living with diabetes, and the data presented at this conference is evidence of our success toward this goal.”


1. Singh H, Alencar G, Sanchez H, et al. Psychosocial Benefits of using the t:slim X2 Insulin Pump with Control-IQ technology: Long-term Outcomes from a Multi-ethnic Adult Cohort with Type 1 Diabetes. Oral presentation at 82nd Scientific Sessions of the American Diabetes Association; June 3-7, 2022; New Orleans, LA.

2. Habif S, Graham R, Singh H, et al. Evaluation of long-term glycemic outcomes by ethnicity in adults with type 1 diabetes using the t:slim X2 insulin pump with Control-IQ technology. Poster presented at 82nd Scientific Sessions of the American Diabetes Association; June 3-7, 2022; New Orleans, LA.

3. Pinsker J, Graham R, Singh H, et al. Long-term Glycemic Control in Adult Participants Using the t:slim X2 Insulin Pump with Control-IQ Technology: Real-World Evidence. Poster presented at 82nd Scientific Sessions of the American Diabetes Association; June 3-7, 2022; New Orleans, LA.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Our Sister Publication

Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy